Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ISRCTN73567594) titled 'Repurposing fusidic acid as a therapeutic for onchocerciasis' on March 13.
Study Type: Interventional
Study Design:
Allocation: Randomized controlled trial
Masking: Open (masking not used)
Control: Active
Assignment: Parallel
Purpose: Treatment
Primary Sponsor: University of Buea
Condition:
Onchocerciasis
Infections and Infestations
Intervention:
The anti-Wolbachia strategy is a clinically validated disease-modifying approach in onchocerciasis, with doxycycline providing established proof of concept through consistent Wolbachia depletion (>90%), long-term sterilisation, and macrofilaricidal activity.
Fusi...